Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Create alerts with multiple filters including highs/low, comparative values, and turning points. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Amgen Inc ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 USA

P: 805-447-1000 F: 805-447-1010

Description:

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.

Key Statistics

Overview:

Market Capitalization, $K 131,546,752
Enterprise Value, $K 131,577,080
Shares Outstanding, K 534,200
Annual Sales, $ 25,979 M
Annual Net Income, $ 5,893 M
Last Quarter Sales, $ 6,238 M
Last Quarter Net Income, $ 1,476 M
60-Month Beta 0.56
% of Insider Shareholders 0.46%
% of Institutional Shareholders 79.01%
Float, K 531,743
% Float 99.54%
Short Volume Ratio 0.65

Growth:

1-Year Return 5.24%
3-Year Return 25.48%
5-Year Return 45.34%
5-Year Revenue Growth 13.00%
5-Year Earnings Growth 46.78%
5-Year Dividend Growth 76.00%

Per-Share Information:

Most Recent Earnings 4.65 on 08/04/22
Next Earnings Date N/A
Earnings Per Share ttm 17.66
EPS Growth vs. Prev Qtr 9.41%
EPS Growth vs. Prev Year 6.16%
Annual Dividend Rate, $ 7.76
Annual Dividend Yield 3.14%
Most Recent Dividend 1.940 on 05/16/22
Next Ex-Dividends Date 08/17/22
Dividend Payable Date 09/08/22
Dividend Payout Ratio 40.14%
Most Recent Split 2-1 on 11/22/99

AMGN Ratios

Ratio
Price/Earnings ttm 13.77
Price/Earnings forward 14.21
Price/Earnings to Growth 2.04
Return-on-Equity % 188.78%
Return-on-Assets % 16.13%
Profit Margin % 22.68
Net Margin % 29.71
Debt/Equity 39.31
Price/Sales 5.08
Price/Cash Flow 10.45
Price/Book 144.04
Book Value/Share 1.71
Interest Coverage 6.60

AMGN Dividends

Date Value
05/16/22 $1.9400
02/14/22 $1.9400
11/15/21 $1.7600
08/16/21 $1.7600
05/14/21 $1.7600
02/11/21 $1.7600
11/13/20 $1.6000
08/14/20 $1.6000
05/15/20 $1.6000
02/13/20 $1.6000
11/14/19 $1.4500
08/14/19 $1.4500
05/16/19 $1.4500
02/14/19 $1.4500
11/15/18 $1.3200
08/16/18 $1.3200
05/16/18 $1.3200
02/14/18 $1.3200
11/16/17 $1.1500
08/15/17 $1.1500
05/15/17 $1.1500
02/13/17 $1.1500
11/14/16 $1.0000
08/15/16 $1.0000
05/13/16 $1.0000
02/11/16 $1.0000
11/12/15 $0.7900
08/13/15 $0.7900
05/12/15 $0.7900
02/10/15 $0.7900
11/10/14 $0.6100
08/12/14 $0.6100
05/13/14 $0.6100
02/11/14 $0.6100
11/12/13 $0.4700
08/14/13 $0.4700
05/14/13 $0.4700
02/11/13 $0.4700
11/13/12 $0.3600
08/14/12 $0.3600
05/14/12 $0.3600
02/13/12 $0.3600
11/15/11 $0.2800
08/16/11 $0.2800
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar